Peter Miller, Optinose CEO
June 13, 2022 10:45 AM EDT
R&D

Look­ing to ex­pand nasal spray in­di­ca­tion, Opti­nose se­cures sec­ond PhI­II win

Lei Lei Wu

News Reporter

Hav­ing got­ten ap­proval for its nasal polyps treat­ment four and a half years ago, Opti­nose is look­ing to ex­pand in­to a pa­tient pop­u­la­tion that’s 10 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times